Drug Discovery Research Screening Libraries
Selleck Chemical LLC FDA-approved Drug Library 100uL/well
A unique collection of 2863 approved drugs for high throughput screening (HTS) and high content screening (HCS). *For Research & Development use only. Product is not intended for drug, household, or human consumption.
Selleck Chemical LLC FDA-approved & Passed Phase I Drug Library 100uL/well
A unique collection of 3176 drugs that are marketed around the world or have passed clinical phase 1 and can be used for high throughput screening (HTS) and high content screening (HCS). *For Research & Development use only. Product is not intended for drug, household, or human consumption.
Cayman Chemical ntIvIral Screeng LIbrary 25uL
An inhibitor of Tie2 and VEGFR2 (IC50s 1 and 3 nM respectively in a HTRF assay) inhibits angiopoietin 1-induced Tie2 autophosphorylation in EA hy926 human endothelial cells (IC50 10 nM)
Selleck Chemical LLC Highly Selective Inhibitor Library 100uL/well
A unique collection of 462 validated highly selective inhibitors with covering over 123 targets. *For Research & Development use only. Product is not intended for drug, household, or human consumption.
Cayman Chemical PestIcIde Screeng LIbrary 50uL
An intermediate in the synthesis of trazadone a potential impurity found in commercial preparations of trazadone
Cayman Chemical Cel Death Screeng LIbrary 50uL
A monohydroxy fatty acid formed by lipid peroxidation of arachidonic acid as well as by rat liver microsomal CYP plasma levels are elevated in patients with angiographically defined coronary artery disease
Apexbio Technology LLC DiscoveryProbe™ Anti-cancer Compound Library, 100uL/well(10 mM solution),96 Well Racks With Screw Cap
1164 anti-cancer compounds Other sizes are available. Please inqury us for quote.
Apexbio Technology LLC DiscoveryProbe™ Epigenetics Compound Library 100uL/well(10 mM solution),96 Well Deep Well Plate
DiscoveryProbe Epigenetics Compound Library comprises 328 small molecules specifically targeting known epigenetic regulators and is carefully curated for biomedical research The compounds in this collection modulate essential epigenetic targets including bromodomains histone deacetylases (HDACs) Janus kinases (JAKs) histone methyltransferases (HMTs) protein Ser/Thr phosphatases and histone acetyltransferases (HATs) Representative compounds include selective HDAC inhibitors bromodomain modulators and methyltransferase-targeting molecules Compounds are approved by recognized institutions or referenced extensively in scientific literature This library facilitates epigenetic mechanism studies target identification chemical biology research and pharmacogenomic exploration
Enzo Life Sciences ADAM17 fluorometric drug discovery kit (1x96wells)
The ADAM17 Fluorometric (also known as fluorimetric) Drug Discovery Kit is a complete assay system designed to screen ADAM17 (TACE) inhibitors using a quenched fluorogenic peptide: Mca-PLAQAV-Dpa-RSSSR-NH2. Mca fluorescence is quenched by the Dpa group until cleavage by proteases separates the two moieties. The assays are performed in a convenient 96-well microplate format. The kit is useful to screen inhibitors of ADAM17, a potential therapeutic target. The compound GM6001 is also included as a prototypic control inhibitor. Alternative name: TACE, A disintegrin and metalloproteinase 17. Applications: Fluorescent detection, HTS Activity assay.
Enzo Life Sciences SCREEN-WELL Adrenergic ligand library (100µl/well)
The adrenergic ligand library contains 83 ligands including endogenous neurotransmitters, agonists, antagonists, and marketed drugs. The library is ideal for screening or identifying recombinant orphan G protein-coupled receptors, target validation, secondary screening, assay development, and other pharmacological applications. The adrenergic ligand library is 1 plate of the larger neurotransmitter library (BML-2810) which contains over 650 CNS receptor ligands. Long Term Storage: -80°C. Applications: HTS .
AdipoGen Withaferin A
Chemical. CAS 5119-48-2. Formula C28H38O6. MW 470.6. Isolated from Withania somnifera. Multifunctional anticancer compound. Amplifies the cellular antioxidant and/or detoxification system, suppresses inflammatory pathways, selectively inhibits tumor cell proliferation and induces apoptosis, suppresses tumor angiogenesis, blocks epithelial-to-mesenchymal transition EMT, tumor invasion and metastasis, alters tumor cell metabolism, induces immunomodulation and downregulates cancer stem cells targets. Sensitizes resistant cancer cells to existing chemotherapeutic agents. Antioxidant. Induces cytoprotective enzymes Nrf2-dependent as well, including SOD, HO-1 heme oxygenase-1, catalase, glutathione peroxidise, glutathione s-transferase and NQO1. Anti-inflammatory agent. Inhibits COX-2 and iNOS expression at protein and mRNA level and PGE2 production. Prevents NF-kappaB activation by inhibiting activation of IKKbeta.
AdipoGen a-Cyano-4-hydroxycinnamic acid
Chemical. CAS 28166-41-8. Formula C10H7NO3. MW 189.2. . Specific monocarboxylate transporter MCT inhibitor. Inhibits mitochondrial lactate and pyruvate transport. Decreases glycolysis. Useful agent for immunometabolism research. Exhibits antitumoral and antiangiogenic activity in gliomas in vivo decreases glycolytic metabolism, migration and invasion. Blocks lactate efflux from glioma cells and sensitizes cells to irradiation. Highly malignant tumors rely heavily on aerobic glycolysis metabolism of glucose to lactic acid even under presence of oxygen Warburg Effect and thus need to efflux lactic acid via MCTs to the tumor micro-environment to maintain a robust glycolytic flux and to prevent the tumor from apoptosis. Inhibiting lactic acid efflux is a very effective therapeutic strategy against highly glycolytic malignant tumors. Common organic matrix-assisted laser desorption/ionization MALDI matrix.